3.4.19.3 analysis application to N-terminal pyroglutamyl unblocking prior to Edman sequential degradation in peptide and protein sequencing 95300, 95303 3.4.19.3 analysis pyroglutamyl aminopeptidase is an auxiliary enzyme in a spectrometric assay for glutaminyl cyclase activity. It is a fast, continuous, and reliable determination of glutaminyl cyclase activity, even in the presence of ammonium ions, during the course of protein purification and enzymatic analysis 649314 3.4.19.3 analysis the enzyme may be a useful single-test adjunct for distinguishing Staphylococcus aureus from Staphylococcus delphini and other members of the Staphylococcus intermedius group -, 754260 3.4.19.3 medicine analysis of enzymic activity in serum of controls and patients diagnosed with pancreatitis, hepatitis, and liver cirrhosis. Pyroglutamyl-aminopeptidase activity decreases selectively in liver cirrhosis compared with all the rest of groups 731717 3.4.19.3 medicine diabetes mellitus affects the levels of hippocampal and hypothalamic PAP-I activities, which may change the metabolic control of its susceptible physiological peptide substrates in the brain 682252 3.4.19.3 medicine examination of Peptoclostridium difficile isolates from children with hematological malignancies, diarrhoea and from healthy neonates. All strains from children with hematological malignancies react with the substrate for L-pyrrolidone arylamidase 727346 3.4.19.3 medicine healthy post-menopausal women show higher values of pyroglutamyl-peptidase I activity than pre-menopausal women. No differences are found in serum pyroglutamyl-peptidase activity between pre- and post-menopausal women with breast cancer. Only post-menopausal women with breast cancer show lower values of pyroglutamyl-peptidase activity than control women 731568 3.4.19.3 medicine overexpression of active PPI in Leishmania major impairs differentiation from the procyclic promastigote to the infective metacyclic promastigote. PPI does not protect against the natural antimicrobial peptide gomesin 681817 3.4.19.3 medicine profiles of macrophage and renal PAP activities may be considered into the elaboration of new potential strategies for preventing nephrotoxicity during cyclosporin treatment 680172 3.4.19.3 medicine the natural oligosaccharide gum from Hakea gibbosa is an effective non-competitive inhibitor. The natural gum may be a promising additive not only for its sustained-release and mucoadhesive properties, but also for its ability to slow the enzymatic degradation of therapeutic polypeptides incorporated in dosage forms 651549 3.4.19.3 additional information C-terminal alpha-helix in the D1 state plays an important role in retaining the D1 state under the stable conditions and in correctly folding into the native structure of PCP-0SH 678264